Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macitentan with RT and TMZ in newly diagnosed Glioblastoma
NCT02254954Phase 1Terminated
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Jan 2015
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of macitentan in glioblastoma (GBM), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoint: Dose-Limiting Toxicities at 10 weeks. Started Jan 2015; status: terminated.
02
Drugs
macitentan
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02254954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02254954.